<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00601159</url>
  </required_header>
  <id_info>
    <org_study_id>200709GP</org_study_id>
    <nct_id>NCT00601159</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC</brief_title>
  <official_title>Phase Ⅱ Study of Gemcitabine and Cisplatin as First Line Combination Therapy in Patients With Triple-negative MBC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of this study is to evaluate the efficacy of gemcitabine and cisplatin as
      first line therapy in patients with triple-negative MBC. 80 patients will be treated into
      this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple-negative breast tumors could contribute to the poor prognosis comparing with luminal A
      breast cancer.Fewer study has revealed that Cisplatin-based therapy may be effective for this
      type breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS (progression free survival)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>side effects</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BRCA1 mutation realtionship with efficacy and toxicity analysis</measure>
    <time_frame>at the end of therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacogenetic analysis</measure>
    <time_frame>collect blood samples before therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>gemcitabine and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin and gemcitabine in the management of triple negative metastatic breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine and cisplatin</intervention_name>
    <description>Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks</description>
    <arm_group_label>gemcitabine and cisplatin</arm_group_label>
    <other_name>gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Give written informed consent prior to study, with understanding that the patient has
             the right to withdraw from the study at any time without prejudice

          -  Be female and ≥18 and ≤75 years of age

          -  Be ambulatory and have ECOG performance stastus of ≤1

          -  Have histological confirmed breast cancer,and the speciman confirmed ER negative,PR
             negatiev, and HER-2 negative by immunochemistry technich of Fudan cancer hospital.

          -  Locally advanced or metastastic breast cancer who didn't receive first-line
             chemotherapy. No matter whether the patient has received anthracyclin or taxane
             treatment as neo-adjuvant or adjuvant treatment.

          -  Have at least one target lesion according to the RECIST criteria.

        Exclusion criteria:

          -  Preganant or lactating women

          -  Advaced patient has received one or more chemotherapies

          -  Chemotherapy within four weeks preceding treatment start

          -  ECOG ≥ 2

          -  Radiotherapy to the axial skeleton within the 4 weeks preceding study treatment start
             or insufficient recovery from the effects of prior radiotherapy

          -  Participation in any investigational drug study within 4 weeks preceeding treatment
             start

          -  Evidence of CNS metastasis

          -  History of another malignacy within the last five years except cured basal cell
             carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast
             cancer

          -  Abnormal laboratory values: hemoglobin &lt; 8. 0g/dl, neutrophil&lt; 1.5×109/L, platelet&lt;
             100×109/L.

          -  serum creatine &gt; upper limit of normal (ULN)

          -  serum bilirubin &gt; ULN

          -  ALT and AST &gt;5×ULN

          -  AKP &gt;5×ULN

          -  Serious uncontrolled intercurrence infection

          -  Life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>+86200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D, Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007 Mar 29;26(14):2126-32. Epub 2006 Oct 2.</citation>
    <PMID>17016441</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2008</study_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Base for drug clinical trials, Fudan University cancer hospital</name_title>
    <organization>Fudan University cancer hospital</organization>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>triple-negative Breast Cancer</keyword>
  <keyword>cisplatin</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

